{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"A Bayesian design intended to simultaneously monitor efficacy and toxicity will be used.\n\nDefinition of Good CR: Conventional criteria for CR (absolute neutrophil count \\> 1,000/uL, platelet count \\> 100,000/uL, marrow with \\<5% morphologic blasts) and additionally the requirements that marrow Minimal Residual Disease (MRD) - detected by 10-color flow cytometry or conventional cytogenetic evaluation - be absent and that the above blood counts be obtained.","groups":[{"description":"Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\npravastatin sodium: Given PO\n\nidarubicin: Given IV\n\ncytarabine: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"35 days","title":"Number of Participants With Good Complete Remission (CR)","type":"PRIMARY","unitOfMeasure":"Participants"}